Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe

conjugated bilirubin
ct scan
renal function
ejection fraction
thrombocythemia
  • 506 views
  • 21 Aug, 2021
  • 178 locations
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)

The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of MF patients

pacritinib
graft versus host disease
stem cell transplantation
  • 24 views
  • 03 Sep, 2021
  • 21 locations
Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

This is a single-arm, open-label study using pacritinib for patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence.

  • 0 views
  • 30 Jul, 2021
  • 1 location
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

/II, study of Pacritinib with Sirolimus and Tacrolimus (PAC/SIR/TAC) for the prevention of acute GVHD after matched related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).

immunosuppression
leukemia
sirolimus
myeloproliferative disorder
tacrolimus
  • 9 views
  • 25 Aug, 2021
  • 2 locations
A Single Arm Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)

This is a single arm, open-label, lead in phase Ib dose confirmation, followed by phase II study with 2 parallel study cohorts. Patients will be pre-screened for presence of 1q21.3 copy number amplification in plasma samples prior to screening process. Only patients with confirmed plasma cell-free DNA (cfDNA) 1q21.3 copy …

cancer treatment
metastasis
immunostimulant
  • 0 views
  • 25 Jan, 2021
  • 1 location